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Although the interactions between sex steroids and GnRH
have been extensively studied, little is known about themech-
anism of estradiol (E2) effects on GnRH secretion. In the
present study, we used retrochiasmatic hypothalamic ex-
plants of 50-d-old male rats, and we observed that E2 signif-
icantly increased the glutamate-evoked GnRH secretion in
vitro within 15 min in a dose-dependent manner. E2 also sig-
nificantly increased the L-arginine-evoked GnRH secretion.
E2 effects were time dependent because the initially ineffec-
tive 109 M concentration became effective after 5 h of incu-
bation. The E2 effects involved the estrogen receptor (ER) 
because they were similarly obtained with the specific ER
agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole.
The use of glutamate receptor agonists and antagonists indi-
cated that E2 effects on GnRH secretion evoked by both glu-
tamate and L-arginine involved the 2-amino-3-hydroxy-5-
methyl-4-isoxazol propionic acid/kainate receptors. Similar
E2 effects on the kainate-evoked secretion were observed
throughout development in both sexes. The observation of
similar E2 effects using explants containing the median em-
inence alone indicated that themedian eminencewas a direct
target for E2 rapid effects on the glutamate-evoked GnRH
secretion. The signaling pathways involved in E2 effects in-
cluded an increase in intracellular calciumand the activation
of protein kinase A, protein kinase C, and MAPK. It is con-
cluded that E2 can stimulate the glutamate- and nitric oxide-
evoked GnRH secretion in vitro through a rapid pathway in-
volving the ER and kainate receptor as well as through a
slower mechanism responding to lower E2 concentrations.
(Endocrinology 146: 2313–2323, 2005)
GNRH IS SYNTHESIZED BY hypothalamic neurons lo-cated in the preoptic region and released in the portal
vascular system in a pulsatile manner (see review in Ref. 1).
Glutamate, the major excitatory neurotransmitter in the hy-
pothalamus (2), can elicit GnRH secretion in vitro (3–5) and
in vivo (6) through activation of ionotropic receptors includ-
ing the N-methyl-d-aspartate (NMDA), kainate, and 2-ami-
no-3-hydroxy-5-methyl-4-isoxazol propionic acid (AMPA)
subtypes. Furthermore, activation of NMDA receptors can
advance the timing of puberty in monkeys and rats (7, 8),
whereas kainate receptors have been involved in the pre-
ovulatory LH surge (9). Estradiol (E2) is known to exert
complex effects on GnRH neuronal function including long
term or genomic effects through binding to estrogen receptor
(ER) subtypes (10). The common concept that E2 only acts on
GnRH neurons through intermediate cells (10) was chal-
lenged after the expression of ER in GnRH neurons has been
reported and confirmed (11–14). E2 has recently been shown
to act directly on GnRH neurons either by increasing cAMP
response element-binding protein phosphorylation (13) or
intracellular calcium ([Ca2]i) levels (15). In addition, E2 can
also exert rapid effects on the GnRH secretion by stimulating
the release of nitric oxide (NO) (16) and this latter mediator
can also evoke GnRH secretion by itself (17).
In a recent study with rat hypothalamic explants, we have
shown that E2 could increase the frequency of pulsatile
GnRH secretion in vitro in a sex- and age-dependent manner
(18). Such in vitro E2-mediated effects required the partici-
pation of kainate and ERs. Similar effects of E2 on kainate
receptor-mediated effects have also been reported in hip-
pocampal (19) or oxytocinergic neurons (20). Although pre-
vious attempts to show involvement of AMPA/kainate re-
ceptors in the onset of puberty had failed (21), we recently
provided some evidence that both kainate receptors and ERs
are involved in the occurrence of precocious puberty after in
vivo administration of E2 (18). To our knowledge, such in-
teractions between E2/ER and kainate receptors in the con-
trol of GnRH secretion and the underlying mechanisms had
not been described so far. To further investigate these inter-
actions, we studied the effect of E2 on the glutamate-evoked
GnRH secretory response using rat hypothalamic explants.
Materials and Methods
Animals and hypothalamic explant incubation
Male and female Wistar rats aged 5, 15, 25, and 50 d were purchased
at the University of Lie`ge. All experiments were carried out with the
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approval of the Belgian Ministry of Agriculture and the Ethical Com-
mittee at the University of Lie`ge.
After decapitation, the hypothalamus was rapidly dissected. The
limits to obtain the retrochiasmatic hypothalamus (RCH) were the cau-
dal margin of the optic chiasma, the rostral margin of the mammillary
bodies, and the lateral hypothalamic sulci (22). To include the preoptic
area (POA) in some explants (RCH-POA explants), the anterior cut was
at the rostral margin of the optic chiasma. Median eminence (ME) ex-
plants were dissected with microscissors under a binocular microscope
(TL2,4, Olympus, Tokyo, Japan). Each explant was transferred into an
individual incubation chamber containing 500 l of phenol-red free
MEM supplemented with glucose, magnesium, glycine, and bacitracin
to achieve final concentrations of 25 mm, 1 mm, 10 nm, 20 m, respec-
tively. The explants were maintained in a static incubator at 37.5 C and
in an atmosphere of 95%O2-5%CO2. In each experiment, 12–15 explants
were studied individually for 4–7.5 h. The medium was collected every
7.5 min and was kept frozen until assayed for GnRH.
GnRH assay
Using 100 l of the incubation medium, GnRH was measured in
duplicate. The RIA procedure has been described in detail previously,
with intra- and interassay coefficients of 14 and 18%, respectively (3, 23).
The CR11-B81 anti-GnRH antiserum (final dilution 1:80,000) was kindly
provided byDr. V. D. Ramirez (Urbana, IL) (24). The data below the limit
of detection (5 pg per 7.5 min) were assigned that value.
Reagents
All reagents, except steroids and R76713, were directly diluted in
MEM. The GnRH secretagogues included glutamate (Sigma, Bornem,
Belgium), N-methyl-D,L-aspartate (NMA, Sigma), kainate (Opika-1
kainic acid, Ocean Produce International, Shelburne, Nova Scotia, Can-
ada), and l-arginine (L-Arg, Sigma). NMDA, AMPA/kainate, or AMPA
receptors were respectively blocked by AP5 (DL-2 aminophosphono-
pentanoic acid, Sigma), DNQX (6,7-dinitroquinoxaline-2,3-dione; Toc-
ris, Illkirch, France) or SYM 2206 (4-aminophenyl-1,2-dihydro-1-methyl-
2-propylcarbamoyl-6,7-methylenedioxyphtalazine; Tocris).
All steroids were initially dissolved in absolute ethanol and subse-
quently diluted in the incubation medium to achieve a final ethanol
concentration of 0.01%. 17-Estradiol, 17-estradiol, progesterone, tes-
tosterone, 5-dihydrotestosterone (5-DHT), and the specific ER ag-
onist PPT (1,3,5-Tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole) were
purchased at Sigma. The ER antagonists tamoxifen and ICI 182.780 were
obtained from Tocris and used at 106 and 107 m, respectively. The
aromatase inhibitor, R76713 (racemic Vorozole; Janssen Pharmaceutica,
Beerse, Belgium) was used at 105 m. R76713 was initially diluted in a
20% polyethyleneglycol solution (3.35 mg/ml, VWR International, Leu-
ven, Belgium) and subsequently diluted in the incubation medium to
achieve a 105 m solution containing 0.02% polyethyleneglycol.
To study protein kinase involvement in E2 effects, the following
inhibitors were used: staurosporine (nonspecific protein kinase inhibi-
tor, 107 m; Sigma), adenosine 3,5-monophosphorothioate Rp isomer
[Rp-cAMP: protein kinase A (PKA) inhibitor (cadenosine 3,5-mono-
phosphorothioate Rp isomer), 105m; Calbiochem, VWR international],
chelerythrine chloride [protein kinase C (PKC)-specific inhibitor, 105m;
Sigma], or PD98,059 (MAPK inhibitor, 2-amino-3-methoxyflavone,
5.105 m; Calbiochem, VWR International). To inhibit phospholipase C,
U73122 was used (Sigma), whereas modulation of calcium levels from
intracellular stores was studied by using caffeine (1,3,7-trimethyxan-
thine) and the sarco(endo)plasmic reticulum Ca2-ATPase (SERCA)
pumps inhibitor, cyclopiazonic acid (both from Sigma).
Study protocols
Effect of E2 on the GnRH secretion evoked by glutamate receptor agonists: dose
and time dependency. We previously reported that millimolar concentra-
tions of glutamate or glutamate receptor agonists were required to
increase the in vitro GnRH secretion in a dose-related manner (3, 25). In
the present experiments, the secretory response of GnRH was evoked
every 37.5 min by a submaximal concentration (102 m) of glutamate or
the glutamate receptor agonists, NMA or kainate. The explants were
stimulated for 7.5 min by the secretagogue (i.e. black boxes for kainate in
Fig. 1A) every 37.5 min (i.e. every fifth fraction of 7.5 min). The explants
were first stimulated by the secretagogue alone, and the GnRH secretory
FIG. 1. A, Representative profile of GnRH secretion from a RCH explant obtained from a 50-d-old male rat and stimulated every 37.5 min with
102 M of kainate as secretagogue (black boxes). After a 7.5-min stimulation with kainate alone (control stimulation), increasing concentrations
of E2 (gray boxes) were added to the medium for two 7.5-min fractions, before and together with kainate. At the end of the experiment, the
secretory response to kainate was studied again in control conditions. B, Effects of E2 (107 M, gray boxes) on the GnRH secretory response
obtained from a 50-d-old male rat hypothalamic explant. The GnRH secretory response was evoked by glutamate as a secretagogue (black boxes)
in the presence of SYM 2206 as an antagonist of the AMPA receptors (hatched bars). The antagonist was used for two 7.5-min fractions before
and one 7.5-min fraction together with the glutamate stimulation, which amounts to 22.5 min of total incubation time with the antagonist. E2
(gray boxes) was added to the incubation medium following the same protocol as explained in A. The experiment was ended by a stimulation
with the secretagogue alone.
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response obtained at that time was considered as the control response.
The effects of E2 on the secretagogue-evoked GnRH secretion were
studied by addition of increasing concentrations of E2 in the incubation
medium7.5min before and togetherwith glutamate (i.e. gray boxes in Fig.
1A). The explants were stimulated repeatedly with the secretagogue at
the same concentration through the entire experiment, and a final stim-
ulation with the secretagogue alone was done to assess the viability of
the explants by comparing the final response with that obtained initially
(Fig. 1A). Based on the dose-response study, we used a 107 m concen-
tration of E2 in subsequent experiments except when stated otherwise.
The effect of reducing the incubation time with E2 was investigated
by shortening to 7.5 min the length of the period during which the
explants were incubated with E2. The effect of increasing the time of
incubation with E2 on the potentiation of the glutamate-evoked release
of GnRH was studied by using 15-d-old female rat hypothalamic ex-
plants, which were stimulated for 7.5 min with 102 m of glutamate
every 37.5 min during an experiment of 7.5 h. After the initial control
stimulation in the absence of E2, the RCH explants were continuously
incubated in either control medium alone (control) or medium added
with 109, 108, or 107m of E2. The explants were incubated in regular
mediumwithout E2 during the last five 7.5-min periods, and the explant
viability was assessed by a glutamate stimulation at the end of the
experiment.
Involvement of glutamate receptor subtypes and NO in E2 effects on the GnRH
secretion. The specific involvement of each ionotropic glutamate receptor
subtype was studied through the use of specific glutamate receptor
antagonists. NMDA, AMPA/kainate, or AMPA receptors were respec-
tively blocked by AP5, DNQX, or SYM 2206. Each antagonist was added
to the incubation medium for two 7.5-min fractions before and one
7.5-min fraction during the secretagogue stimulation (Fig. 1B), which
amounts to 22.5 min of total incubation time with the antagonist.
We used L-Arg as a NO precursor to evoke GnRH secretion. Based
on a dose-response study in comparison with 102 m of glutamate, a 2
 102 m concentration of L-Arg was used to evoke a GnRH secretory
response from hypothalamic explants. The effects of E2 on the GnRH
secretory response evoked by L-Arg as a secretagogue was studied by
using the same experimental design as that shown in Fig. 1A.DNQXwas
used in the same way as explained above (see Fig. 1B), to examine the
involvement of AMPA/kainate receptor in E2 effect on the L-Arg-
evoked GnRH secretion.
Steroid and receptor specificity of E2 effects. The specificity of E2 effects on
the glutamate-evoked GnRH secretion was investigated with different ste-
roids. The explants were first stimulated by glutamate alone (control stim-
ulation) and then in the presence of 107m of E2 (as a positive control). The
same experimental protocol was used to study the effects of 17-estradiol,
progesterone, and testosterone on the glutamate-evoked GnRH secretion.
These steroids were used at the same concentration as E2 (107 m) except
E2-BSA, which was also used at 106 m.
The involvement of classical ERs in E2 amplification of the glutamate-
evoked GnRH secretion was investigated by the use of the ER antag-
onists tamoxifen and ICI 182.780 and the specific ER agonist PPT. The
ER antagonists were used in the same way as the glutamate receptor
antagonists. After a control stimulation with glutamate alone (control
stimulation) and glutamate in the presence of E2 (positive control),
increasing concentrations of PPT were tested according to the experi-
mental pattern shown in Fig. 1A.
The aromatase inhibitor R76713 was used at 105 m based on dose-
response studies (data not shown). The aromatase inhibitor and 5-DHT
were used to verify that the testosterone effect on the glutamate-evoked
GnRH secretion required its prior aromatization into E2. In this exper-
iment, the explants were first stimulated by glutamate alone (control
stimulation) and then by glutamate in the presence of testosterone (pos-
itive control). The aromatase inhibitor was then used for 22.5 min such
as described in the case of the glutamate receptor antagonists (Fig. 1B),
whereas the effect of 5-DHT was studied through its addition to the
medium for two 7.5-min fractions before and together with the gluta-
mate stimulation (same design as Fig. 1A).
E2 effects on GnRH-evoked secretion obtained from RCH-POA, RCH, or ME
explants.After dissection and transfer to the incubator, the three different
types of explants were first stimulated with the secretagogue alone as
a control response (glutamate, NMA, or kainate) and then with the
secretagogue in the presence of E2 (same design as in Fig. 1A).
E2 effects in relation to age and sex. The effects of age and sex on the
kainate-evoked GnRH secretion were studied by using RCH hypotha-
lamic explants from male and female rats at 5, 15, 25, or 50 d. Hypo-
thalamic explants were subjected to the same protocol as in Fig. 1A with
kainate as the stimulatory secretagogue.
Intracellular signaling pathways involved in E2 effects. To study protein
kinase involvement in E2 effects, the following protein kinase inhibitors
were used: staurosporine, Rp-cAMP, chelerythrine chloride, or
PD98,059. To inhibit phospholipase C, U73122 was used, whereas the
participation of [Ca2]i was studied using caffeine and cyclopiazonic
acid.
Analysis of the GnRH secretory response evoked by
a secretagogue
At least four explants were used in each experimental group. Each
explant was used as its own control. The secretory response (picogram
per 7.5-min fraction) was calculated as the difference between the levels
in the 7.5-min fractions obtained immediately before and during expo-
sure to the secretagogue. To compare the results displayed in different
graphs and tables, data were expressed as percentages of the control
response. Such a transformation did not affect the statistical analysis
because identical significance levels were obtained using data expressed
as absolute levels (picogram per 7.5 min) or percentages relative to
controls. The GnRH values (in picograms) for the secretagogue stimu-
lation alone (control stimulation) are also mentioned in the tables or
graph legends.
Data were analyzed by one-way ANOVA with correction for re-
peated measures except for comparisons of E2 effect between males and
females (two individual experiments) in which unpaired one-way
ANOVA was used. Each test was followed by Newman-Keuls posttest
when the threshold for significance of differences (P 0.05) was reached
(GraphPad Prism software; GraphPad, San Diego, CA).
Results
Involvement of the kainate receptor subtype in E2 effects on
GnRH secretion evoked by glutamate receptor agonists
or NO
Figure 2 shows the effect of increasing concentrations of E2
on the GnRH secretory response evoked by glutamate, kai-
nate, or NMA used as secretagogues. In each case, the stim-
ulation of RCH explants (obtained from 50-d-old male rats)
with the secretagogue alone elicited a GnRH secretory re-
sponse that was considered as the control response. The
baseline GnRH secretory level was usually undetectable and
did not increase during incubation with E2 alone (data not
shown). A dose-related increase in the GnRH secretory re-
sponse was caused by E2 and was significant from a con-
centration of 108 or 107 m in E2 when the explants were
stimulated by kainate (Figs. 1A and 2A) or glutamate (Fig.
2A), respectively. No effect of E2 was observed when GnRH
secretionwas evoked byNMA (Fig 2A). The kainate receptor
subtype was specifically involved because the AMPA/kai-
nate receptor antagonist DNQX completely prevented E2
effect, whereas E2 was still able to increase the glutamate-
evoked secretion in the presence of the NMDA or AMPA
receptor antagonists AP5 or SYM 2206, respectively (Fig. 2B).
In the absence of E2, a decrease in the GnRH secretory re-
sponse was caused by each of the three glutamate receptor
subtypes antagonists used separately, indicating that they all
participated in the glutamate-evoked GnRH secretion.
Because E2 was reported to increase the basal GnRH se-
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cretion in a NO-dependent manner (16), we investigated the
effect of E2 on the GnRH secretory response evoked by
L-Arg, a NO precursor. Based on the dose-response effect of
L-Arg on GnRH secretion in comparison with glutamate
(Table 1), a 2  102 m concentration of L-Arg was used.
Using increasing concentrations of E2, the L-Arg-evoked
GnRH secretory response was significantly increased by E2
at concentrations of 108m or higher (Fig. 3A). Such an effect
involved the AMPA/kainate receptor subtype because the
significant increase in L-Arg-evoked GnRH secretory re-
sponse induced by 107 m of E2 (L-Arg: 9  1 pg or 100 
9%; L-ArgE2: 143 9%, P 0.05; L-Arg vs. L-ArgE2) was
prevented by the AMPA/kainate receptor antagonist DNQX
at 106m (L-ArgDNQX: 87 8%; L-ArgE2DNQX: 93
6%; P  0.05, L-ArgE2 vs. L-ArgE2DNQX; P  0.05,
L-ArgDNQX vs. L-ArgE2DNQX). When used alone,
DNQX also significantly decreased the L-Arg-evoked GnRH
secretion (P  0.05, L-Arg vs. L-Arg DNQX).
Time dependency of E2 effects
When E2 was used for a total of 15 min (i.e. the 7.5-min
fractions before and during exposure to glutamate), a sig-
nificant stimulatory effect was observed using 107 m of E2
(Fig. 2, Table 2). When the steroid was used only for 7.5 min
together with glutamate, a significant stimulation could be
observed, but a 106 m concentration of E2 was required
FIG. 2. A, Effects of increasing concentrations of E2 on theGnRHsecretory response evoked by different excitatory amino acids (EAAs) including
glutamate (Glu), kainate (Ka), and NMA. The results (mean  SD) are expressed in percentage of the control response (102 M of the EAA used
alone). The design is similar to the experiment illustrated in Fig. 1A. The number of explants (n) for each experiment is mentioned on the graph
and the values (mean  SD in picograms) for the control GnRH secretory response evoked by each of the three different secretagogues are
displayed in the legend box. The experiments used RCH hypothalamic explants obtained from 50-d-old male rats. *, P 0.05, E2 together with
EAA vs. controls with EAAalone (before and after exposure to E2). B, Effects of antagonists of glutamate receptor subtypes on the E2 stimulation
of the glutamate-evokedGnRH secretion obtained from50-d-oldmale rat hypothalamic explants. Antagonists of AMPA/kainate (DNQX), NMDA
(AP5), and AMPA (SYM 2206) receptors were used at a 106 M concentration. The value for the GnRH secretory response evoked by glutamate
alone (control stimulation) is 12  1 pg, and the number of explants (n) for each experiment is mentioned on the graph. a, P  0.05,
glutamateglutamate receptor antagonist vs. control glutamate stimulation; b, P  0.05, E2-treated vs. control glutamate stimulation.
TABLE 1. Mean (SD) GnRH secretory response from RCH
hypothalamic explants (n  4) obtained from 50-d-old male rats
Secretagogue Concentration (M)
GnRH secretory response (mean  SD)
pg/7.5 min % of Glu stimulation
Glu 102 33  4 100  13
L-Arg 103 a a
L-Arg 5  103 9  3 26  8
L-Arg 102 15  3 44  10
L-Arg 5  102 55  8 163  24
The explants were stimulated by glutamate or increasing concen-
trations of L-Arg.
a Value below the detection level.
FIG. 3. Effects of increasing concentrations of E2 on the L-Arg-
evoked GnRH secretion (open bars) in comparison with E2 (107 M,
gray bar) effects on the glutamate (Glu)-evoked GnRH secretion (con-
trol response, black bar). RCH hypothalamic explants were obtained
from 50-d-old male rats (n 4). The GnRH secretory response evoked
by glutamate was 14  2 pg, and the response evoked by L-Arg was
9 1 pg. *,P 0.05, E2secretagogue (glu or L-Arg) vs. secretagogue
alone.
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(control: 27 4 pg per 7.5min or 100 15%; E2 107m: 141
32%; E2 106 m: 178  47%; P  0.05 control vs. E2 106 m).
When explants were continuously incubated with differ-
ent concentrations of E2 for a prolonged period of 7 h (Fig.
4), a significant increase in the glutamate-evoked GnRH se-
cretion was observed at lower concentrations of E2 (109 and
108m) thatwere previously found to be ineffective. After 4 h
of incubation, a 108 m concentration of E2 became as effec-
tive as 107 m, and after 5.5 h, 109 m of E2 started to be
significantly active. Noteworthy, in the control group, there
was no significant difference in the secretory responses of
GnRH evoked by glutamate alone during the whole exper-
iment, whereas after the explants were incubated with E2 for
7 h, the GnRH secretory response to the control stimulation
at the end of the experiment was significantly greater than
the initial control response evoked by glutamate alone.
Steroid and receptor specificity of E2 effects
To confirm the specificity of E2 effects, we tested the effects
of progesterone and 17-estradiol on the glutamate-evoked
GnRH secretion. Both steroids had no effect on the gluta-
mate-evoked GnRH secretion (Table 2). Using 107 m of
testosterone, the glutamate-evoked GnRH secretion was sig-
nificantly increased in an aromatase-dependent manner be-
cause the aromatase inhibitor R76713 prevented that effect,
whereas the nonaromatizable androgen 5-DHT had no ef-
fect (Table 2). Two different ER antagonists, ICI 182.780 and
tamoxifen, totally prevented the stimulating effect of E2 on
GnRH secretion evoked by glutamate (Table 2). The involve-
ment of ERwas further investigated through the use of PPT,
a specific ER agonist that was recently described (26). PPT
resulted in a significant dose-dependent stimulation (from
106 m) of the glutamate-evoked GnRH secretion (Table 3).
ME as a site of E2 effects on GnRH-evoked secretion
Asmentioned before, the cell bodies of GnRH neurons are
located in the POA of the rat hypothalamus. The RCH ex-
plants do not contain the POA, and then no or very few
GnRH cell bodies can be found (27). In the aforementioned
experiments, E2 effects were studied using RCH hypotha-
lamic explants that contain only GnRH axons and the ter-
minals located in the ME. We then studied E2 effects on the
TABLE 2. Mean (SD) GnRH secretory response evoked by
glutamate expressed as percentage of control response (glutamate
alone, 102 M), in the presence of different steroids and steroid
antagonists
n Steroid Antagonist(for 22.5 min)
Steroid concentration (for 15 min)
0 (pg) 0 (Control in %) 107 M
4 E2 15  4 100  26 150  28a
E2 Tamoxifen 90  12 84  17
4 E2 13  2 100  15 168  14a
E2 ICI 182.780 93  11 83  13
4 17-E2 36  8 100  22 103  25
4 P 93  34
4 T 22  2 100  10 140  12a
4 5-DHT 106  10
4 T R76713 22  2 104  11 100  7
In each experiment, four to five RCH explants from 50-d-old male
rats were used. The ER antagonists tamoxifen and ICI were used at
106 M and 107 M, respectively. The aromatase inhibitor (R76713)
was used at 105 M. P, Progesterone; T, testosterone.
a P  0.05, E2 vs. control.
FIG. 4. Effects of different concentrations of E2 (109, 108, and 107 M) on the GnRH secretory response evoked by glutamate (102 M) every
37.5 min (five 7.5-min fractions). The RCH explants, obtained from 15-d-old female rats, were first incubated in MEM alone until the first
glutamate stimulation (control stimulation) and then one group (n 4) was further incubated withMEM alone (MEM), whereas the three other
groups (n  4 in each group) were continuously incubated with different concentrations of E2. At the end of the experiment, the explants were
incubated with MEM alone during 30 min (four 7.5-min fractions) before the last glutamate control stimulation. The values for the GnRH
secretory response evoked by the glutamate alone (control stimulation in picograms) are shown in the legend. a, P  0.05, glutamateE2 vs.
first glutamate stimulation (control); b, P  0.05: first glutamate stimulation vs. last glutamate stimulation.
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GnRH secretory response in RCH explants containing the
POA (RCHPOA, Table 4). In addition, the ME, which con-
tains GnRH terminals only and the neighboring afferent ax-
ons, astroglial cells, and tanycytes aswell as endothelial cells,
was also used to study E2 effects. E2 (107 m) increased the
GnRH secretion evoked by glutamate or kainate, but not
NMA, in a similar manner using the three types of explants
(Table 4). These data suggest that ME is a direct target of
kainate receptor-mediated stimulatory effects of E2 onGnRH
secretion.
Sex and age independence of E2 effects
Using RCH explants frommale and female rats aged 5, 15,
25, and 50 d, GnRH secretion evoked by kainate was signif-
icantly increased by E2 in a dose-dependent manner (108 to
106m, Fig. 5). At the highest E2 concentration studied (106
m), a significant sex difference was observed. This sex dif-
ferencewas variablewith age because E2 effects were greater
in males than females at 5 and 50 d, whereas females showed
higher responses at 15 and 25 d. The GnRH control response
evoked by glutamate alone was higher in females than in
males at the four studied ages.
Intracellular signaling pathways involved in E2 effects
The involvement of [Ca2]i levels in E2 effects on the
GnRH secretory response was also studied (Table 5). The
depletion of ryanodine receptor- and inositol triphosphate
(IP3) receptor-dependent [Ca2]i stores by caffeine did not
prevent E2 effects. Cyclopiazonic acid (CA), an inhibitor of
SERCA pumps, prevented the replenishment of the [Ca2]i
stores after stimulation, thus maintaining a higher concen-
tration of [Ca2]i in the cell. In the presence of CA, the control
GnRH secretory response to glutamate was significantly in-
creased, whereas the E2-potentiating effects on the gluta-
mate-evoked GnRH secretory response were not prevented
(Table 5). The above results indicate that an increase in
[Ca2]i from intracellular stores is not involved in E2 effect.
On the contrary, calcium from extracellular environment
appears to be involved in E2 effects because nickel, an in-
hibitor of calcium entry (28), and nifedipine, an inhibitor of
L-type voltage-gated calcium channels, prevented E2 effects
(Table 5).
Because an increase in [Ca2]i can activate protein kinases,
we investigated the involvement of different protein kinases
in E2 effect (Table 5). U73122, which is a phospholipase C
inhibitor, prevents the formation of IP3 and DAG and then
inhibits the subsequent release of IP3 receptor-dependent
[Ca2]i and the phosphorylation of PKC. U73122 had no
effect on the control glutamate stimulation, whereas it pre-
vented E2 effects. From the above results using caffeine, we
hypothesized that this inhibitory effect resulted from the
inhibition of PKC rather than the IP3 pathway. Such an
involvement of PKC in E2 effect was confirmed by the use
of chelerythrine chloride, a PKC inhibitor, which prevented
E2 effect. Other inhibitors of protein kinases including stau-
rosporine (PKA and PKC inhibitor), Rp-cAMP isomer (spe-
cific PKA inhibitor) and PD98,056 (MAPK inhibitor) were
used, and each of them prevented E2 effects. When used
alone, the specific PKAandPKC inhibitors slightly decreased
GnRH secretory response to glutamate stimulation. How-
ever, this decrease was significant only when PKA and PKC
were both inhibited by staurosporine.
Discussion
Using rat hypothalamic explants, we report here that E2
rapidly increased (within 7.5–15 min) the GnRH secretion
evoked by glutamate in a dose-dependent manner through
a pathway involving ERs and the kainate receptor subtype.
Using rat hypothalamic slices, Drouva et al. (29) reported that
GnRH secretion evoked by a potassium depolarization was
increased by E2 within 6 min, and similar effects have been
found in the quail (30). To our knowledge, it is the first time
that E2 and kainate receptors are reported to interact in a
mechanism resulting in an increase of the GnRH secretory
response evoked by glutamate. In previous experiments (18),
we showed that, in the rat, E2 could increase the frequency
of the pulsatileGnRH secretion in vitro and that such an effect
was correlated to the occurrence of sexual precocity in vivo.
TABLE 3. Mean (SD) GnRH secretory response evoked by
glutamate (102 M) in the presence of increasing concentrations of
the ER-specific agonist PPT
Steroid Concentration (M)
None 100  12
E2 107 148  15a
PPT 108 106  9
PPT 107 102  11
PPT 106 116  11a
PPT 105 133  15a
The results are expressed as percentage of the control stimulation
(glutamate alone, 34 4 pg). GnRH secretory response was obtained
from RCH hypothalamus (n  4) of 50-d-old male rats.
a P  0.05, E2 vs. control.
TABLE 4. E2 effect on glutamate-receptor-mediated secretion of GnRH using hypothalamic explants (n) obtained from 50-d-old male rats
Explants
RCH  POA RCH ME
Control  E2 Control  E2 Control  E2
Glutamate 100  11 133  11a 100  14 130  14a 100  9 123  13a
(22  3 pg) (7  1) (7  1)
Kainate 100  14 132  8a 100  10 143  10a 100  14 124  13a
(23  3 pg) (6  1) (7  1)
NMA 100  5 113  1 100  10 103  12 100  14 114  9
(21  1 pg) (7  1) (7  1)
The explants included both the POA and the RCH or the RCH only or the ME. The control GnRH secretory response was obtained by
stimulating each explant with one of the secretagogues alone (102 M, control response) and the results are expressed as percentage of the control
response (mean  SD, values in picograms are also given in parentheses.). E2 concentration was 107 M.
a P  0.05, estradiol vs. control.
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Although the parameters of GnRH secretion studied here are
different, the similarities in the requirement of ER and kai-
nate receptors are striking.
Although the validity of the data obtained using our par-
adigm has been addressed previously, the possibility of ex-
citotoxic effects due to the high glutamate concentrations
used and the significance of glutamate-evoked vs. sponta-
neous GnRH secretion warrant some discussion. To our
knowledge, in all the published studies using glutamate or
NMDA/NMA to stimulate GnRH secretion from hypotha-
lamic explants (4, 31), the required concentrations are in the
10- to 50-mm range, which is similar to those required in our
paradigm, whereas the effective concentrations on cultured
immortalized GnRH neurons are slightly lower (between 0.1
and 10 mm) (32). This discrepancy suggests that the bio-
availability of glutamate receptor agonists is reduced in the
explant incubation system when compared with a cell cul-
ture system. In our paradigm, we showed that the GnRH
secretory response to a depolarization was preserved as long
as NMA concentrations less than 100 mmwere used (23). As
shown in the present study, the sustained capacity of the
explants to respond for several hours to repeated glutamate
stimulation and the recovery of the initial response after
several hours of incubation was consistent with an absence
of excitotoxic effects of short-term glutamate stimulations.
Another technical issue is whether endogenous secretory
pulses could affect the response to a secretagogue added in
the medium. As a matter of fact, a secretory episode evoked
by veratridine depolarization (33) or glutamate receptor stim-
ulation (34) has previously been shown to be followed by a
period of refractoriness to endogenous or exogenous secreta-
gogues. Such refractoriness results froman inhibitory autofeed-
back of the GnRH secretion involving the GnRH(1–5) subprod-
uct, which is present in the medium after endopeptidase
degradation of the decapeptide (34). The duration of that re-
fractory period is age dependent and related to the develop-
mental changes in the frequency of the pulsatile GnRH secre-
tion (33, 34). According to those studies, the hypothalamic
explants obtained from rats at different ages were stimulated
every 37.5 min, which is outside the refractory period.
FIG. 5. Effects of increasing concentrations of E2 (1010 to 106 M) on the kainate-evoked GnRH secretion in vitro using RCH hypothalamic
explants obtained in male and female rats at 5, 15, 25, and 50 d of postnatal age. The results (mean  SD) are expressed in percentage of the
control response (kainate alone, 102 M) and E2 was added for two 7.5-min fractions, i.e. before and together with glutamate. The values for
the GnRH secretory response evoked by the glutamate alone (control stimulation in picograms) are shown in the legend. a, P  0.05, E2 vs.
control in female; b, P  0.05, E2 vs. control in male; c, P  0.05, male vs. female.
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Our present study shows that E2 increased the glutamate-
evokedGnRH secretion in a dose-dependentmanner. E2was
effective at concentrations between 108 and 106 m that
were similar to those required to increase the frequency of
pulsatile GnRH secretion in vitro (18). Although these con-
centrations were in the supraphysiological range, they are
consistentwith the concentrations that are reported by others
to affect GnRH secretion in vitro (16), [Ca2]i levels in GnRH
neurons (15) or kainate-evoked currents in hippocampal (19)
and oxytocinergic neurons (20). In addition, we also showed
that lower concentrations of E2 (108 and 109 m) signifi-
cantly increased the glutamate-evoked GnRH secretion
when the explants were incubated with E2 for several hours.
From these results, it can be inferred that the dose depen-
dency of E2 effects is influenced by the exposure length of the
explants to E2 and that effects such as those described here
could require lower E2 concentrations in the in vivo condi-
tions. Whereas the rapid E2 effects disappeared immediately
when the steroid was no longer present, it seemed that the
continuous and prolonged incubation of the explantswith E2
initiated additional mechanisms that appeared to be acti-
vatedwithin 3–4 h and persisted after removal of E2 from the
medium. These two time-related components of the response
to E2 could be consistent with an involvement of both rapid,
nongenomic, and slow or genomic mechanisms.
The E2 effects on the glutamate-evoked GnRH secretion
were steroid and stereo specific, and similar effects could be
observed with testosterone. The effects of testosterone were
prevented by an aromatase inhibitor, which indicates that
testosterone was effective after its aromatization into E2.
These data are in agreement with the localization of the
aromatase enzyme (35) and mRNA (36) in the arcuate and
ventromedial hypothalamic nuclei.
It has been recently shown that GnRH neurons express
ER (11). Our experiments indicate that E2 increased the
glutamate-evoked GnRH secretory response through an ER-
mediated mechanism because the ER antagonists tamoxifen
and ICI 182.780 prevented E2 effects. However, our data
using the specific ER agonist PPT (26) suggest that the ER
subtype is involved in E2 effects. The higher effective con-
centrations of PPT (106 m) were consistent with the con-
centrations 10–100 times higher than E2 that are needed to
achieve effects similar to E2 either in vitro (38) or in vivo (39).
Further studies using specific ER antagonists and/or ER
agonists will be needed to verify that ER is the only ER
subtype involved in E2 effects.
E2 can rapidly act in various biological systems through
the activation of secondary effectors such as [Ca2]i, cAMP,
and/or protein kinases (for review see Ref. 40). Because it
was shown that E2 cannot directly induce kainate receptor
opening as it does at the NMDA receptors in hippocampal
neurons (41), the E2 effects could possibly involve an indirect
effect through activation of phosphorylation processes that
would subsequently activate kainate receptors. Here E2 was
found to increase the glutamate-evoked GnRH secretion
through activation of protein kinases as E2 effects were pre-
vented using specific inhibitors of PKA, PKC, and MAPK. A
slight inhibitory effect of the protein kinase inhibitor stau-
rosporine on the glutamate-evoked GnRH secretionwas also
observed, which is agreement with the involvement of PKA
and PKC in the GnRH secretory process that has been de-
scribed in GnRH cell lines (42). The upstream effectors to the
protein kinase cascade could include the entry of calcium
from the extracellular environment and a subsequent in-
crease in [Ca2]i level because blocking of the L-type calcium
channel by nifedipine or the inhibition of extracellular Ca2
TABLE 5. Mean (SD) GnRH secretory response evoked by glutamate (Glu), in the presence of E2 and modulators of intracellular
calcium release ([Ca2]i, caffeine, cyclopiazonic acid), L-type calcium channel antagonist (nifedipine), or different protein kinase (PK)
antagonists
n Glu (102 M)  antagonist Antagonist activity Control response (pg)
E2 concentration (for 15 min)
0 (Control) 107 M
4 Caffeine (5  103 M) [Ca2]i depletor 14  2 100  12 178  21a
86  6 161  24a
4 Cyclopiazonic Ac (105 M) SERCA inhibitor 15  2 100  11 185  19a
145  3c 263  34a,b
4 Nickel Inhibitor of Ca2 entry 11  1 100  8 155  30a
74  8c 76  0b,d
5 Nifedipine (2  106 M) L-type calcium channel antagonist 10  2 100  15 147  22a
81  14c 75  15b
9 U73122 (2  106 M) PLC inhibitor 14  3 100  22 150  22a
91  26 93  29b
4 Staurosporine (107 M) PK inhibitor 12  1 100  7 150  4a
90  4c 95  4
5 Rp cAMP (105 M) PKA inhibitor 35  5 100  15 168  14a
95  15 95  16b
5 Chel Chloride (105 M) PKC inhibitor 12  1 100  7 150  4a
94  4 90  4b
5 PD 98056 (5  105 M) MAPK (ERK1/2) inhibitor 11  1 100  7 155  13a
100  12 102  12b
The RCH explants (n) were obtained from 50-d-old male rats. The data are expressed in percentage of the control response (in picograms)
obtained after stimulating the explants with glutamate alone.
a P  0.05, control vs. E2 (either without or with the antagonist).
b P  0.05, glutamate/E2/antagonist vs. glutamate/E2.
c P  0.05, control/antagonist vs. control.
d The calculated secretory response for each explant gave the same result, and SD was thus zero.
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entry (by nickel) prevented E2 effects on the GnRH secretory
response to glutamate. In addition, the inhibitor of SERCA
pumps, CA (28), significantly increased the GnRH secretory
response evoked by glutamate alone as well as the E2-po-
tentiating effect on that response. After a glutamate stimu-
lation, the [Ca2]i levels would return to basal levels through
the action of Ca2 pumps, such as the SERCA, that will
reconstitute the [Ca2]i stores. In the presence of a SERCA
inhibitor, there will be a sustained increase in [Ca2]i levels
that would account for the increased GnRH secretory re-
sponse to glutamate that was observed. However, the effect
of CA was additive to E2 effect, which indicates that the
increase in [Ca2]i levels responsible for E2 effects on the
glutamate-evoked GnRH secretion would mainly be of ex-
tracellular origin.
In addition to the effects on the glutamate-evoked GnRH
secretion, we also found that E2 could increase the L-Arg-
evoked GnRH secretory response. This effect could be due to
an increase in NO release because E2 has been reported to
stimulate NO synthase (43). This hypothesis is supported by
the study of Prevot et al. (16) reporting that nanomolar con-
centration of E2 increased the basal GnRH secretion in vitro
from ME through an increase in NO release. We reported
here that the E2-induced increase in the NO-mediated GnRH
secretion was dependent on kainate receptor function, sug-
gesting an indirect interaction between E2 andNO. Thus, our
data suggest the existence of a still-unidentified link between
the intracellular E2-ER complex and the kainate receptors
that could mediate NO effects as well.
A possible cross-talk point between E2 and kainate recep-
tor could involve the MAPK pathway because MAPK phos-
phorylation after E2 or kainate stimulation has been reported
in neurons (44), glial cells (45, 46), or endothelial cells (43).
Such effects require the activation of PKC (44) or phospho-
lipase C (45) that were also involved in E2 potentiation of
glutamate-evoked GnRH secretion. Recently ER subtypes
have been identified in GnRH neurons (for review, see Ref.
14), and direct effects of E2 on GnRH neurons were reported
(13, 15). However, in our conditions, a direct action of E2 on
GnRH cell bodies is unlikely because E2 increased the glu-
tamate-evoked GnRH secretion obtained from retrochias-
matic explants in which GnRH cell bodies are virtually ab-
sent (27). In addition, E2 was found to be effective in ME
explants. Similar effect of E2 on GnRH secretion at the ME
was also reported by others (16), which supports the idea that
E2 can act at the level of the ME with possible involvement
of glial or endothelial cells. Consistent with this latter hy-
pothesis, the kainate receptor subunits GluR7 mRNA (47)
andGluR5–6 protein (47, 48) have been reported in glial cells
of the ME (48). The detection of ER in glial cells of the ME
(49) and the fact that, in our experiments, ER is involved
further supports the concept of glial cells as mediators of E2
effects on the glutamate-evoked GnRH secretion. Moreover,
GnRH secretion can be modulated by glial cells (50), and E2
can increase GnRH secretion in vitro through the astrocytic
release of growth factors such as TGF (51). In our condi-
tions, the involvement of ER in E2 effects suggests that they
are more likely to be mediated through intermediate cells
because there is increasing evidence that ER are the recep-
tors mediating direct effects of E2 on GnRH neurons (14, 15,
52).
We recently described that the frequency of pulsatile
GnRH secretion from RCH explants could be stimulated
by E2 through a kainate- and ER-dependent mechanism
(18). Importantly, such a mechanism did operate in the
female only before sexual maturation (5 and 15 d), in
contrast to the E2 amplification of the glutamate-evoked
secretion of GnRH that occurred in both sexes and at every
age studied. In our conditions, pulsatile GnRH secretion
cannot be endogenously generated from isolated ME ex-
plants and requires either RCH neurons impinging on
GnRH axons/terminals or GnRH cell bodies (27). We
therefore hypothesized to a dual E2- and kainate receptor-
mediated effect on GnRH secretion. One is located in the
ME and involves the terminal GnRH secretory processes,
irrespective of sex and developmental stage. Another one
is located in the RCH and modulates the frequency of the
GnRH pulsatile secretion in a sex- and developmental-
dependent manner. We could then hypothesize that a pos-
sible sexual dimorphism in the response to the glutamate
stimulation is blunted by the supraphysiological concen-
trations of E2 that were used to study E2 rapid effects. This
hypothesis is consistent with the fact that E2 can act at
lower concentrations if the incubation period is increased.
Further studies are warranted to investigate the duality of
E2 effects on the glutamate-evoked GnRH secretion.
Glutamate is a major excitatory amino acid in the neu-
roendocrine functions (2) and has been reported to increase
GnRH secretion either in vivo (6) or in vitro (3–5). Glutamate
has also an important role in the estrus cycle because glu-
tamate receptor antagonists can block the preovulatory LH
surge when administered in vivo (53–55). Because we re-
ported a terminal effect of E2 on the ME, we could hypoth-
esize that the principal cell type involved in E2 effect could
be the tanycytes and/or endothelial cells that both have been
involved in the occurrence of the preovulatory surge (56, 57).
In the case of tanycytes, their involvement in E2 effect on the
glutamate-evoked GnRH secretion is supported with the
localization of ERs (37) at the level of the ME, together with
the colocalization of kainate receptor subunitswith tanycytes
markers (48). These observations are in favor of an E2/ER/
NO/kainate receptor-mediated pathway stimulating the re-
lease of GnRH at the ME level, with a possible relevance to
the occurrence of a preovulatory surge. According to our
data, it is, however, too early to elaborate a complete mech-
anistic scheme.
In conclusion, using rat hypothalamic explants, E2 rapidly
increased the glutamate-evoked GnRH secretion in a dose-
and steroid-dependent manner. This E2 effect involved kai-
nate and ERs and required protein kinase activation.
Through such a mechanism, E2 rapidly modulated GnRH
secretion in both sexes and would likely imply interactions
between GnRH terminals and interneurons and glial or en-
dothelial cells located in the ME. Further studies will aim at
elucidating the intracellular mechanisms linking the E2-ER
complex and kainate receptor stimulation as well as the
localization of these effects.
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